Q-omics provides the consensus-scored SBF1P2 profile across patient tissues and cancer cell-line models. SBF1P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SBF1P2 is differentially expressed in 4, with the highest sampling consensus in COAD. Additionally, SBF1P2 RNA expression shows 6,984 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight UVM, COAD, and READ as cancer lineages where SBF1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SBF1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SBF1P2 survival associations across molecular data types. SBF1P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SBF1P2 RNA expression–survival associations across cancer types. High SBF1P2 expression shows unfavorable associations in OV, COAD, CHOL and LUSC, but favorable associations in UVM and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SBF1P2 RNA expression.
This table summarizes SBF1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SBF1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SBF1P2 shows lower tumor expression in THCA and BRCA and higher tumor expression in COAD and LIHC. The COAD box plot shows higher SBF1P2 RNA expression in tumor versus normal tissue (log2 FC = +0.078, t-test p = .003).
This table shows molecular features associated with SBF1P2 in patient tissues and cancer cell lines. In patient samples, SBF1P2 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
